Portfolio company Cagent Vascular secured $41M to advance its dual-modality IVL platform.
Cagent Vascular is dedicated to improving the treatment of cardiovascular disease, a leading cause of mortality and poor quality of life worldwide
Cagent Vascular is dedicated to improving the treatment of cardiovascular disease, a leading cause of mortality and poor quality of life worldwide. The company’s vision is to be the leader in angioplasty technology with the first and only serration balloon to restore blood flow.